Literature DB >> 33870708

Impact of Chronic Hypertension and Antihypertensive Treatment on Adverse Perinatal Outcomes: Systematic Review and Meta-Analysis.

Sukainah Y Al Khalaf1,2, Éilis J O'Reilly1,3, Peter M Barrett1,2, Debora F B Leite4, Lauren C Pawley5, Fergus P McCarthy2,6, Ali S Khashan1,2.   

Abstract

Background Maternal chronic hypertension is associated with adverse pregnancy outcomes. Previous studies examined the association between either chronic hypertension or antihypertensive treatment and adverse pregnancy outcomes. We aimed to synthesize the evidence on the effect of chronic hypertension/antihypertensive treatment on adverse pregnancy outcomes. Methods and Results Medline/PubMed, EMBASE, and Web of Science were searched; we included observational studies and assessed the effect of race/ethnicity, where possible, following a registered protocol (CRD42019120088). Random-effects meta-analyses were used. A total of 81 studies were identified on chronic hypertension, and a total of 16 studies were identified on antihypertensive treatment. Chronic hypertension was associated with higher odds of preeclampsia (adjusted odd ratio [aOR], 5.43; 95% CI, 3.85-7.65); cesarean section (aOR, 1.87; 95% CI, 1.6-2.16); maternal mortality (aOR, 4.80; 95% CI, 3.04-7.58); preterm birth (aOR, 2.23; 95% CI, 1.96-2.53); stillbirth (aOR, 2.32; 95% CI, 2.22-2.42); and small for gestational age (SGA) (aOR, 1.96; 95% CI, 1.6-2.40). Subgroup analyses indicated that maternal race/ethnicity does not influence the observed associations. Women with chronic hypertension on antihypertensive treatment (versus untreated) had higher odds of SGA (aOR, 1.86; 95% CI, 1.38-2.50). Conclusions Chronic hypertension is associated with adverse pregnancy outcomes, and these associations appear to be independent of maternal race/ethnicity. In women with chronic hypertension, those on treatment had a higher risk of SGA, although the number of studies was limited. This could result from a direct effect of the treatment or because severe hypertension during pregnancy is a risk factor for SGA and women with severe hypertension are more likely to be treated. The effect of antihypertensive treatment on SGA needs to be further tested with large randomized controlled trials.

Entities:  

Keywords:  antihypertensive; chronic hypertension; fetal outcome; meta‐analysis; neonatal outcome; pregnancy; systematic review

Year:  2021        PMID: 33870708     DOI: 10.1161/JAHA.120.018494

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  4 in total

1.  Optimal blood pressure target to prevent severe hypertension in pregnancy: A systematic review and meta-analysis.

Authors:  Makiko Abe; Hisatomi Arima; Yuichi Yoshida; Ako Fukami; Atsushi Sakima; Hirohito Metoki; Kazuhiro Tada; Asako Mito; Satoshi Morimoto; Hirotaka Shibata; Masashi Mukoyama
Journal:  Hypertens Res       Date:  2022-02-08       Impact factor: 3.872

2.  Chronic hypertension and risk of preterm delivery: National Longitudinal Study of Adolescents to Adult Health.

Authors:  Erin Delker; Gretchen Bandoli; Yvette LaCoursiere; Karen Ferran; Linda Gallo; Eyal Oren; Sheila Gahagan; Gladys A Ramos; Matthew Allison
Journal:  Paediatr Perinat Epidemiol       Date:  2022-02-02       Impact factor: 3.103

3.  Reduction in Preterm Preeclampsia after Contingent First-Trimester Screening and Aspirin Prophylaxis in a Routine Care Setting.

Authors:  Cristina Trilla; Josefina Mora; Nuria Ginjaume; Madalina Nicoleta Nan; Obdulia Alejos; Carla Domínguez; Carmen Vega; Yessenia Godínez; Monica Cruz-Lemini; Juan Parra; Elisa Llurba
Journal:  Diagnostics (Basel)       Date:  2022-07-28

4.  Mediterranean Diet and Lifestyle Habits during Pregnancy: Is There an Association with Small for Gestational Age Infants? An Italian Single Centre Experience.

Authors:  Rachele De Giuseppe; Manuela Bocchi; Silvia Maffoni; Elsa Del Bo; Federica Manzoni; Rosa Maria Cerbo; Debora Porri; Hellas Cena
Journal:  Nutrients       Date:  2021-06-05       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.